Keywords: Gilead Sciences, Atripla, Truvada, New Zealand, Funding, HIV treatment, PHARMAC

New Zealand to fund Gilead's Atripla and Truvada

Article | 27 November 2012

Print This

New Zealand’s Pharmaceutical Management Agency PHARMAC says that, effective December 1, it will fund two new combination HIV treatments ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in